BD (Becton, Dickinson and Company) announced that "embecta" will be the name of the independent, publicly traded company that will hold BD's diabetes care business, which markets diabetes care products, such as insulin syringes and pen needles.
The spinoff, which was announced previously, is expected to close in the second quarter of 2022.
Devdatt Kurdikar, Worldwide President of BD Diabetes Care, will become CEO of embecta upon completion of the spinoff.
